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Bedaquiline, a diarylquinoline for the treatment of multidrug-resistant tuberculosis (TB), relies on exposure-dependent killing.
As data on drug exposure in specific populations are scarce, pharmacokinetic studies may be of interest. No simple and robust
validated liquid chromatography-tandemmass spectrometry (LC-MS/MS) method has been reported to date. Therefore, a new
method using a quadrupole mass spectrometer was developed for analysis of bedaquiline andN-monodesmethyl bedaquiline
(M2) in human serum, using deuterated bedaquiline as the internal standard. The calibration curve was linear over a range of
0.05 (lower limit of quantification [LLOQ]) to 6.00 mg/liter for both bedaquiline andM2, with correlation coefficient values of
0.997 and 0.999, respectively. The calculated accuracy ranged from 1.9% to 13.6% for bedaquiline and 2.9% to 8.5% for M2.
Within-run precision ranged from 3.0% to 7.2% for bedaquiline and 3.1% to 5.2% for M2, and between-run precision ranged
from 0.0% to 4.3% for bedaquiline and 0.0% to 4.6% for M2. Evaluation of serum concentrations in a patient receiving bedaqui-
line showed high levels at the end of treatment, reflecting accumulation of the drug. More observational pharmacokinetic data
are needed to relate altered drug concentrations to clinical outcome or adverse drug effects. A simple LC-MS/MSmethod to
quantify bedaquiline andM2 levels in human serum using a deuterated internal standard has been validated. This method can be
used in clinical studies and daily practice.
Bedaquiline is a diarylquinoline and was approved by theUnited States Food and Drug Administration (FDA) in 2012
under the accelerated-approval program. This drug is indicated
for treatment of multidrug-resistant pulmonary tuberculosis
(MDR-TB) in combination with other active anti-TB drugs in
adults without other treatment options (1). This new anti-TB
drug, formally known as TMC207, showed exposure-dependent
killing of Mycobacterium tuberculosis (2, 3). The drug is metabo-
lized by cytochrome P 450 enzyme 3A4 (CYP3A4) to its 5-fold-
less-active metabolite N-monodesmethyl bedaquiline (M2) (4).
Bedaquiline therapy is started in a loading dose of 400mg once
daily for 2 weeks followed by 200 mg 3 times per week for 22
weeks. This dosing regimenwas chosen because pharmacokinetics
(PK) modeling predicted gradual accumulation in plasma and
tissues (4).
At this time, little data on PK in patients with advanced
MDR-TB or suffering from comorbidities are available apart from
the data that were collected in the clinical studies (4). However,
variability in the PK of antituberculosis drugs is considerable and
altered drug exposure may translate to variations in clinical out-
comes (5, 6). Clearly, there is a need for more-descriptive (popu-
lation) PK studies on bedaquiline to determine predictors of ex-
posure, drug-drug interaction (7), and PK-pharmacodynamics
(PD) relationships. TheWorldHealthOrganization has released a
guide for the use of bedaquiline and encourages additional evalu-
ation of this new drug (8).
As bedaquiline serum concentrations may be altered in
MDR-TB patients with comorbidities, a suitable method of anal-
ysis is needed. Only advanced analytical methods using high-per-
formance liquid chromatography (HPLC) inductively coupled
plasma (ICP) mass spectrometry (MS) have been presented pre-
viously (9, 10). These methods were used for metabolite profiling
of bedaquiline in feces. Due to their advanced setup requirements,
these analytical procedures are generally not available in clinical
laboratories that perform routine monitoring of serum concen-
trations of anti-TB drugs. In addition, despite their advanced
setup, the results determined with the combination of HPLC and
ICP are not as specific as those determined with tandem mass
spectrometry (MS/MS), as it measures only the bromine. Simpler
analytical methods using liquid chromatography coupled to tan-
dem mass spectrometry are described in reports of the clinical
studies, but the data lack the detail necessary to be useful for clin-
ical laboratories as guidance to develop their own analytical
methods (11). Therefore, the purpose of this study was to develop
a simple and robust LC-MS/MS method without extensive
sample processing, using deuterated bedaquiline as the internal
standard, to quantify bedaquiline and M2 serum concentra-
tions in MDR-TB patients.
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Analysis. Bedaquiline, M2, and D6-bedaquiline (internal standard) (Fig.
1)were obtained from Janssen Pharmaceuticals (Beerse, Belgium).Water,
acetonitrile, ammonium acetate, and acetic acid were all of suitable ana-
lytical grade. Pooled human serum samples were made available accord-
ing to the guidelines of the University Medical Center Groningen.
Bedaquiline stock solutions of 500 mg/liter of dimethyl sulfoxide
(DMSO)–methanol (50:50) were prepared separately and used for the
preparation of calibration standards and quality control (QC) samples
using blank human serum. The amounts of stock solution added to the
serum did not exceed 5% of the total volume. Calibration standards and
QC samples were freshly prepared on the first validation day and stored at
20°C for use on the other validation days. Concentrations of the stan-
dards andQC samples are listed in Table 1. The internal standard solution
was prepared by diluting a 500 mg/liter bedaquiline-D6 stock solution to
0.1mg/liter withmethanol-acetonitrile (precipitation reagent) (160:840).
Samples were prepared by adding 750l precipitation reagent to 10l
serumand subsequent vortexmixing for 1min. The vials were centrifuged
for 5 min at 11,000 rpm, and 5 l of the upper layer was injected into the
LC-MS/MS system.
The analysis was performed on a triple-quadrupole LC-MS/MS sys-
tem (Thermo Scientific, San Jose, CA, USA) with a MS Pump Plus and
Surveyor autosampler (Finnigan). The mass spectrometer was a TSQ
Quantum Access Max mass spectrometer. The temperature of the au-
tosampler was set at 10°C. A HyPURITY C18 analytical column (Thermo
Scientific, Interscience, Breda, TheNetherlands) (50 by 2.1mm; pore size,
3m)was used for chromatographic separation, and the temperaturewas
set at 20°C. The mobile phase had a flow rate of 500l/min and consisted
of purified water, acetonitrile, and an aqueous buffer (containing ammo-
nium acetate [10 g/liter], acetic acid [35 mg/liter], and trifluoroacetic
anhydride [2ml/liter] in water). The elution gradient is shown in Table 2.
The method had a run time of 2.6 min.
The MS system was configured using the positive electrospray ioniza-
tionmode and selected reactionmonitoring (SRM)with a spray voltage of
3,500 V, a capillary temperature of 350°C, and sheath gas and auxiliary
pressures of 35 and 10 arbitrary units, respectively. Mass transitions for
bedaquiline were 555.1 m/z to 58.4 m/z, for D6-bedaquiline were 561.2
m/z to 64.4m/z, and forM2were 541.1m/z to 480.1, using a scan width of
0.5m/z. Collision energywas determined at 34 electron volts (eV) for both
transitions. Xcalibur software version 2.0.7 (Thermo Fisher, San Jose, CA,
USA) was applied for peak height and peak area integration for all com-
ponents.
Analytical method validation. The criteria for validation of the
method included selectivity and sensitivity (i.e., determination of the
lower limit of quantitation [LLOQ]), linearity, accuracy and precision,
recovery, matrix effect, process efficiency, and dilution integrity. The cal-
ibration curve for bedaquiline consisted of 8 samples with concentrations
of 0.05, 0.25, 0.50, 1.00, 2.00, 4.00, 5.00, and 6.00mg/liter. Quality control
(QC) samples with 4 different concentrations of bedaquiline were used,
where the LLOQ was 0.05 mg/liter, the low concentration was 0.25 mg/
liter, the medium concentration was 2.50 mg/liter, and the high concen-
tration was 5.00 mg/liter. The effect of endogenous substances was exam-
ined by an infusion ion suppression test using 6 lots of different blank
serums, and the results were compared to the response seen at the LLOQ.
During 3 days, a single calibration curve was analyzed each day and accu-
racy wasmeasured by evaluation of five determinations perQC sample on
three consecutive days. Precision was divided into within-run and be-
tween-run data using the same method as described above for the accu-
FIG 1 Chemical structures. Structure a, bedaquiline; structure b, M2; structure c, D6-bedaquiline.
TABLE 1 Validation results
Criterion
Value at indicated QC concn level
LLOQ Low Medium High
Nominal concn (mg/liter)
Bedaquiline 0.05 0.25 2.5 5
M2 0.05 0.25 2.5 5
Accuracy (bias [%])
Bedaquiline 13.6 2.9 1.9 4.2
M2 8.5 2.9 5.4 5.9
Within-day precision (CV [%])
Bedaquiline 7.2 5.1 3.0 3.0
M2 4.4 3.2 3.6 3.1
Between-day precision (CV [%])
Bedaquiline 4.3 0.0a 2.5 0.0a
M2 4.6 0.0a 1.4 2.6
Matrix effect (bias [%])
Bedaquiline 103.0 103.5 98.5
M2 100.8 96.6 95.0
Recovery (bias [%])
Bedaquiline 103.5 98.4 106.8
M2 99.7 101.7 103.9
Total process efficiency (bias [%])
Bedaquiline 106.6 101.8 105.2
M2 100.5 98.3 98.7
a No additional variation was added to the intraday imprecision value as a result of
measurements on separate days.




0.00 5 95 0
1.50 5 0 95
2.20 5 0 95
2.21 5 95 0
2.60 5 95 0
a A, ammonium acetate 5.0 g/liter, acetic acid 100% 25 ml/liter, trifluoroacetic acid
(99.95%) 2 ml/liter; B, ultrapure water; C, acetonitrile LC-MS (Biosolve).
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racy determinations. All three calibration curves were assessed with the
use of Analyze-it to assess the linear regression of the 8-point calibration
curve. For each accuracy and precision determination, concentration bias
and coefficient of variation (CV) were calculated per run and each value
was not allowed to exceed 20% for LLOQand 15% for the otherQC levels.
Within-run, between-run, and overall CV values were calculated with the
use of one-way analysis of variance (ANOVA).
Procedures to evaluate recovery, matrix effect, and process efficiency
were derived from the work of Matuszewski and coworkers (12). The
recoverywas calculated by dividing the peak area value of the extract of the
spiked matrix by the peak area value of the spiked extract of a blank
matrix. The matrix effect was tested by dividing the peak area value of the
spiked extract of the blank matrix by the peak area value of the spiked
extraction solution. The process efficiencywas determined by dividing the
peak area value of the extract of the spikedmatrix by the peak area value of
spiked extraction solution. Recovery, matrix effect, and process efficiency
were all determined at three concentrations (low, medium, and high) in
quintuplicate in a single run. To determine the dilution integrity, on three
consecutive days, a QC sample with bedaquiline at a concentration of 12
mg/liter plasma was diluted 10 times and then analyzed in quintuplicate.
The stability of bedaquiline and M2 was tested under different test
conditions, including storage stability and freeze-thaw stability at low-
and high-level QC. The storage stability of bedaquiline and M2 was ex-
amined by storing QC samples at room temperature (20°C25°C), in a
refrigerator at 4°C, and after sample preparation in the autosampler at
10°C. Stability was also tested using five freeze-thaw cycles at20°C. All
stability tests were done using two different QC levels (low and high) in
five determinations per concentration. Stability values were defined in
terms of changes in concentration and should be15%. Long-term sam-
ple stability was not tested, as data were provided by Janssen Pharmaceu-
ticals.
Clinical application and compassionate-use program. Bedaquiline
was made available in a compassionate-use program in The Netherlands
before it became commercially available. Data were collected through
review of the medical records of the patients who received bedaquiline
within the compassionate-use program. Informed consent was obtained
from the participants. The study was evaluated by the local ethics com-
mittee andwas found to be in accordance withDutch legislation due to its
retrospective nature (METc 2013-491).
RESULTS
The mean retention time of bedaquiline was 1.9 min, the mean
retention time of bedaquiline-D6 was also 1.9 min, and the mean
retention time ofM2 was 1.8 min (Fig. 2). Examining the selectiv-
ity of this analytical method, no interfering peaks from endoge-
nous substances were observed at the retention time of bedaqui-
line orM2 in any of the six different lots of human serum (Fig. 2).
The calibration curves were linear over a range of 0.05 (LLOQ)
to 6.00 mg/liter, and the correlation coefficient (R2) values were
0.997 for bedaquiline and 0.999 for M2. The calibration curve
parameters are presented in Table 3. The calculated accuracy
ranged from 1.9% to 13.6% for bedaquiline and 2.9% to 8.5% for
M2.Within-run precision ranged from3.0% to 7.2% for bedaqui-
line and 3.1% to 5.2% for M2, and between-run precision ranged
from 0.0% to 4.3% for bedaquiline and 0.0% to 4.6% forM2. The
results of the accuracy and precision determinations for all QC
levels for bedaquiline and M2 are shown in Table 3.
Recovery, matrix effect, and process efficiency data for be-
daquiline and M2 are displayed in Table 1.
Results of determinations of the stability of bedaquiline and
M2 under different test conditions are shown in Table 4. Mea-
sured (low and high) concentrations of QC samples for the freeze-
thaw stability biased between 7.2% and 9.0% for bedaquiline and
between 7.7% and 8.0% for M2, compared to the initial concen-
trations. Stability was determined by measuring QC samples
stored at 4°C, and data differed by 1.1% to 4.4% from the nominal
concentrations. After storage at room temperature for 72 h, the
concentrations biased from 11.6% to 6.6% for bedaquiline
and 7.8% to 0.5% for M2, compared to the initial concentra-
tions. After sample preparation, the concentrations stored in the
autosampler for 240 h biased between 3.5%and 6.7% for bedaqui-
line and between 2.0 and 2.6% for M2 from the nominal concen-
trations. Samples were stable for 1 year at 20°C for bedaqui-
line and M2 (data on file).
Clinical application; compassionate-use program. A 31-
year-old female who resided in a highly TB-burdened country
presented with fever despite having received two short courses of
antimicrobial drugs. Her chest X-ray revealed characteristic signs
of TB. M. tuberculosis was isolated from the sputum, revealing
resistance to isoniazide, rifampin, ethambutol, and moxifloxacin.
FIG 2 Chromatogram of bedaquiline, M2, and D6-bedaquiline. Chromato-
gram at lowest limit of quantitation: a, bedaquiline; b, M2; c, D6-bedaquiline,
d, blank serum.
LC-MS/MS Determination of Bedaquiline
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She was started on a regimen containing pyrazinamide, kanamy-
cin, linezolid, and prothionamide. Nausea and vomiting necessi-
tated replacement of prothionamide by cycloserine. After 4
months of treatment, bedaquiline, provided in a compassionate-
use program, was added to optimize the treatment regimen. As
part of routine supportive care, the MDR-TB treatment regimen
was further optimized based onMIC testing andmeasurements of
drug serum concentrations. The concentration-time profiles of
bedaquiline and M2 can be observed in Fig. 3. Bedaquiline drug
concentrations at the end of treatment were higher than the values
previously reported at week 8 (13). M2 values were low, as ex-
pected (3). No drug-drug interactions were expected as no
CYP3A4 inhibitors were coadministered. As the treatment was
nearly completed and,more importantly, the patient tolerated the
drug very well, no dose adjustments were made.
DISCUSSION
This report describes the design and validation of a simple and
rapid analysis method using a triple-quadrupole LC-MS/MS sys-
tem for the quantification of bedaquiline and its metaboliteM2 in
human plasma and deuterated bedaquiline as the internal stan-
dard. This LC-MS/MS method showed good accuracy and preci-
sion. The calibration curve was linear within a range of 0.050
(LLOQ) to 6.00 mg/liter and was found to be in accordance
with the expected bedaquiline andM2 concentrations in serum
(11, 13).
Compared to the analytical range of the procedure described
by Rustomjee and coworkers (11), the analytical range of our pro-
cedure had an elevated higher limit of quantitation (HLQ) (2.0
versus 6.0 mg/liter). This may be advantageous, as dilution of the
sample and subsequent rerun of a diluted sample become super-
fluous. However, our LLOQ was a little higher. This was of no
clinical relevance, as the LLOQ of our procedure was designed for
patients on bedaquiline treatment.
As already mentioned, a major advantage of this LC-MS/MS
method is that it uses a simple protein precipitation which makes
it suitable for PK monitoring. The two ICP-MS methods de-
scribed earlier used liquid-liquid extraction and solid-phase ex-
traction and were specifically designed for metabolite profiling
and not for PKmonitoring (9, 10). The run time is very short since
the retention time of bedaquiline is 1.9 min. This facilitates high
sample throughput. This is in line with the strategy of the World
Health Organization designed to increase the capacity of high-
quality laboratory systems using modern diagnostics for early,
rapid, and accurate detection of TB, as it demands only one LC-
MS/MS system to support a clinical therapeutic drug monitoring
(TDM) service (14). In addition, bedaquiline sample stability is
sufficient to enable transportation to a centralized laboratory. Re-
cently, the first results of an international proficiency testing pro-
gram for measurement of tuberculosis drugs were presented (15).
Programs for drug susceptibility testing have been around for
many years (16), but programs for measuring tuberculosis drug
plasma concentrations have not. Participation in such an inter-
laboratory program provides additional quality assurance on top
of intralaboratory QC monitoring, ensuring that plasma drug
concentrations aremeasured accurately. In our opinion, bedaqui-
line should be used in such a program when plasma levels are
measured frequently.
Since the antimicrobial action of bedaquiline is exposure de-
pendent (2, 3), it is necessary, as with any drug with exposure-
dependent killing characteristics, that target exposures are
reached. Current data from animal studies on optimal drug expo-
sure have not yet been translated to and validated in human stud-
ies. Due to the lack of clinical phase III data, including intensive
TABLE 4 Stability analysis results
Criterion (time of determination)
% bias at indicated
QC concn level
Low High
Autosampler stability (240 h)
Bedaquiline 6.7 3.5
M2 2.6 2.0
Benchtop stability (72 h)
Bedaquiline 11.6 6.6
M2 7.8 0.5
Freeze-thaw stability (after 5 freeze-thaw cycles)
Bedaquiline 7.2 9.0
M2 7.7 8.0
Stability at 4°C (240 h)
Bedaquiline 1.4 1.2
M2 2.7 4.4 FIG 3 Bedaquiline concentration time curve. Solid circles represent bedaqui-
line; open circles represent M2.
TABLE 3 Calibration lines
Compound y intercept ( SD) Slope ( SD) Correlation coefficient Regression coefficient
Bedaquiline 0.000170 0.000166 0.0699 0.00120 0.99676 0.99352
M2 0.00132 0.000634 0.487 0.00460 0.99902 0.99804
Alffenaar et al.
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PK sampling,MIC evaluation, and clinical outcome data, no clear
target can be given. Hopefully, the data from the STREAM trial
(NCT02409290) will provide relevant data. An average steady-
state plasma concentration of 0.6mg/literwas observed in patients
who received bedaquiline in addition to a background regimen,
showing a culture conversion rate higher than that seen with pa-
tients who received a placebo (13). To attain this target in patients
suspected to have altered pharmacokinetics due to reduced food
intake, drug-drug interactions, or altered disease state, bedaqui-
line serum concentration measuring may be helpful. We should
try to optimize treatment in order to prevent treatment failure,
especially in patients infected with extensively resistant M. tuber-
culosis strains with few treatment options left (17).
For first-line treatment, it has already been shown that drug
exposure predicts outcomes (6). In cases of treatment of MDR-
TB, that conclusion is less clear, predominantly due to a lack of
data. A recent study showed that fluoroquinolone resistance de-
veloped in over 10%of the patients studied (18), likely because the
pharmacokinetic-pharmacodynamic targets were not reached in a
substantial proportion of the patients (19). Recent phase III stud-
ies evaluating new strategies for treatment of TB did not include
measurements of drug concentrations as a covariate in the analysis
of the primary outcome of the study (20–22). As evaluation of
drug concentrations in relation to the susceptibility of the patho-
gen may help to explain differences in treatment responses, it is
highly desirable that pharmacokinetics should become part of fu-
ture phase III studies (23). Therefore, plasma drug concentrations
of new drugs such as bedaquiline and delamanid will receivemore
attention in future studies as well as in daily practice. Also, in cases
of off-label use or in studies evaluating the bactericidal activity of
drug combinations, information on drug exposure is helpful to
explain treatment outcome (24–26).
The describedmethodwas developed formonitoring bedaqui-
line serum concentrations in daily practice because it meets the
criteria for TDM but is also suitable for clinical pharmacokinetic
studies or clinical trials to further investigate the use of bedaqui-
line in specific TB patient groups suffering from comorbidities or
drug-drug interactions.
Conclusion. A simple LC-MS/MS method to quantify be-
daquiline and M2 in human serum using deuterated bedaquiline
as the internal standard has been developed and validated. This
method can be used in daily practice and in clinical studies evalu-
ating drug exposure in relation to clinical outcome.
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